A new study reveals that generic drugs now comprise 63% of the Medicare Part D market.
Wolters Kluwer Health, a division of Wolters Kluwer, released the results of a study that looks at key statistical outcomes of the Medicare Part D (MPD) prescription drug program. The study found the following: fewer patients entered the coverage gap in 2007 with 15.5% entering versus 17.1% in 2006; patients are willing to stay on their branded medication while in the coverage gap for the first 60 to 90 days. However, with the average stay in the gap increasing to over 100 days and the overall cost of branded medications rising, many patients are choosing to replace their branded drugs with generic alternatives. Claims for generics climbed to 63% of all MPD claims, a jump of nearly 6 percentage points over 2006. For more information visit